AstraZeneca’s Camizestrant Clears India’s SEC Review The Story: AstraZeneca’s camizestrant has received a positive SEC recommendation in India for HR-positive, HER2-negative advanced breast cancer wit...
Key Highlights: Implications: AstraZeneca’s positive SEC recommendation could accelerate Etcamah’s entry into India’s emerging ESR1-mutated breast cancer segment without a local Phase III ...
